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Previous research has indicated that the adenovirus protein complex named RID, derived from the E3 transcription unit,
functions to remove the receptors named Fas/Apo1/CD95 (Fas) and epidermal growth factor receptor (EGFR) from the
surface of cells. (The RID complex is composed of the RID and RID polypeptides, previously named 10.4K and 14.5K,
respectively.) In response to RID, Fas and EGFR appear to be internalized into endosomes and degraded in lysosomes. Fas
is a death receptor in the tumor necrosis factor (TNF) receptor superfamily. RID inhibits apoptosis via the Fas pathway,
presumably because RID gets rid of Fas. Earlier work further showed that another adenovirus E3-coded protein, E3-14.7K,
inhibits apoptosis induced by TNF. Most of the above studies have been conducted using viable virus mutants that lack one
or more of the genes for RID, E3-14.7K, or E1B-19K (this protein, coded by the E1B transcription unit, also inhibits apoptosis
via the TNF and Fas pathways). Some studies have also been conducted with the genes for RID or E3-14.7K transiently or
stably transfected into cells. We now report a new approach to studying the E3 genes. We have constructed four E1-minus
replication-defective vectors that have all the E3 genes deleted from their natural position and then reinserted, in different
permutations, into the deleted E1 region under control of the cytomegalovirus immediate early promoter. Vector Ad/RID only
has the genes for RID and RID. Vector Ad/14.7K only has the gene for E3-14.7K. Vector Ad/RID/14.7K only has the genes
for RID, RID, and E3-14.7K. Vector Ad/E3 has all E3 genes, but there are two missense mutations in the gene for
Adenovirus Death Protein. These vectors expressed RID and/or E3-14.7K, as expected. The RID-expressing vectors forcedINTRODUCTION
In common with other viruses, human adenoviruses
(Ad) encode proteins that maintain infected cell viability
for a period sufficient for virus replication to occur (Te-
odoro and Branton, 1997; Chinnadurai, 1998; White, 1998;
Krajcsi and Wold, 1998; Wold and Tollefson, 1998; Mahr
and Gooding, 1999). With Ads, the immediate early E1A
proteins block the effects of interferons (IFN) by inhibit-
ing the assembly of transcription factors required for
transcription of IFN-inducible genes (Leonard and Sen,
1996; Routes et al., 1996). At later times in infection, a
small Ad-coded RNA, named VA-RNAI, inhibits the activ-
ity of the double-stranded RNA-activated protein kinase,
PKR, and thereby prevents PKR from shutting down cel-
lular transcription (Mathews and Shenk, 1991). Two pro-
teins coded by the Ad E1B transcription unit, named
E1B-55K and E1B-19K, prevent intrinsic cellular apopto-
sis. E1B-55K binds the tumor repressor protein p53 and
inhibits its ability to induce apoptosis (Chinnadurai, 1998;
1 These authors contributed equally to this work.
299White, 1998; Vogelstein et al., 2000). A protein coded by
the E4 transcription unit, named E4ORF6, binds E1B-55K
and p53 and thereby contributes to the inhibition of
p53-mediated apoptosis (Nevels et al., 2000; Cathomen
and Weitzman, 2000; Querido et al., 2001). E1B-19K, a
partial functional homolog of Bcl-2, acts at several levels
to inhibit activation of the proapoptotic caspases (Chin-
nadurai, 1998; White, 1998; Wold and Chinnadurai, 2000;
Shen and White, 2001).
Several Ad proteins also inhibit apoptosis induced by
effector cells of the immune system. Such proteins in-
clude E1B-19K and at least four proteins coded by the E3
transcription unit. The E3 protein named E3-gp19K pre-
vents recognition of Ad-infected cells by cytotoxic T-
lymphocytes (CTL) (Blair and Hall, 1998; Mahr and Good-
ing, 1999; Wold et al., 1999; Wold and Chinnadurai, 2000;
Horwitz, 2001). E3-gp19K is an integral membrane pro-
tein that localizes to the endoplasmic reticulum (ER) by
virtue of an ER retention signal (Paabo et al., 1987; Jack-
son et al., 1990). In the ER, E3-gp19K binds newly syn-
thesized major histocompatibility (MHC) class I antigens
and prevents their transport to the cell surface where
they could interact with the T cell receptor (Andersson etthe internalization and degradation of Fas and EGFR, and t
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binds TAP and acts as a tapasin inhibitor, and thereby
prevents the association between TAP and class I anti-
gens (Bennett et al., 1999). Thus, E3-gp19K inhibits killing
by CTL (Andersson et al., 1987; Burgert et al., 1987; Rawle
et al., 1989; Hermiston et al., 1993).
Other Ad proteins inhibit killing by alternate mecha-
nisms. As part of the mechanism by which CTL kill
targets, activated CTL express ligands in the tumor ne-
crosis factor (TNF) family, such as Fas ligand (also
known as CD95L and Apo1L), TNF related apoptosis
inducing ligand (TRAIL) (also known as Apo2L), and
TNF (TNF) (Nagata, 1997; Walczak and Krammer, 2000).
These ligands interact with their cognate receptors in the
TNF receptor superfamily, namely, Fas, TRAIL Receptor
1/DR4 (TRAIL-R1), TRAIL Receptor 2/DR5 (TRAIL-R2), and
TNFR1, respectively, on target cells (Strasser et al., 1995).
This interaction triggers clustering of the receptors and
activation of a series of protein–protein interactions that
leads to activation of the caspases. Among these inter-
actions, proteins named FADD and procaspase-8 as-
semble with the clustered receptors; this results in cleav-
age and activation of caspase-8, which in turn eventually
causes activation of “effector” caspases such as
caspase-3.
E1B-19K blocks apoptosis induced by TNF (Gooding et
al., 1991a; White et al., 1992), by a Fas-specific monoclo-
nal antibody that triggers Fas-mediated apoptosis
(Hashimoto et al., 1991; Tollefson et al., 1998), and by
TRAIL (Tollefson et al., 2001), apparently by mechanisms
described above. Further, E1B-19K interacts with a con-
formationally altered form of Bax in mitochondria; it
blocks the oligomerization of Bax, and it thereby inhibits
cytochrome c release and caspase-9 activation (Perez
and White, 2000; Sundararajan et al., 2001; Sundararajan
and White, 2001).
Three E3-coded proteins also play a role in inhibiting
apoptosis through the death domain receptors. The E3-
14.7K protein (Tollefson and Wold, 1988) inhibits apopto-
sis through the TNFR1 (Gooding et al., 1988, 1990; Horton
et al., 1990, 1991; Krajcsi et al., 1996), TRAIL (Tollefson et
al., 2001), and reportedly the Fas (Chen et al., 1998)
pathways. E3-14.7K has been shown to interact physi-
cally with several cellular proteins, and its mechanism of
action may involve these proteins (Chen et al., 1998; Li et
al., 1997, 1998, 1999; Lukashok et al., 2000; Ye et al.,
2000).
Induction of apoptosis through the death domain recep-
tors is also inhibited by the E3 protein named RID (receptor
internalization and degradation) (Tollefson et al., 1998). RID,
formerly known as the E3-10.4K/14.5K protein complex
(Tollefson et al., 1991), is composed of two distinct polypep-
tides, RID (formerly 10.4K protein) and RID (14.5K protein)
(Cladaras and Wold, 1985; Tollefson et al., 1990a,b). Both
RID and RID are integral membrane proteins that local-
ize to the plasma membrane and other cytoplasmic mem-
brane structures (Krajcsi et al., 1992a,b; Stewart et al., 1995).
RID prevents TNF-induced cell killing (Gooding et al., 1991b)
by a mechanism that includes inhibition of TNF-induced
translocation of the 85-kDa cytosolic phospholipase A2
(cPLA2) from the cytosol to membranes, and the concordant
inhibition of TNF-induced synthesis of arachidonic acid
(Dimitrov et al., 1997). RID inhibits apoptosis by clearing Fas
(Tollefson et al., 1998; Shisler et al., 1997; Elsing and
Burgert, 1998), TRAIL-R1 (Tollefson et al., 2001; Benedict et
al., 2001), and TRAIL-R2 (Benedict et al., 2001) from the cell
surface. As they leave the cell surface, Fas, TRAIL-R1, and
TRAIL-R2 enter endosomes which are transported to lyso-
somes where the receptors are degraded (Tollefson et al.,
1998, 2001). RID similarly stimulates the internalization and
degradation of the epidermal growth factor receptor (EGFR)
(Carlin et al., 1989; Tollefson et al., 1991; Hoffman et al.,
1992). RID also reportedly internalizes the receptors for
insulin and insulin-like growth factor-1 (Kuivinen et al.,
1993).
Many of the conclusions regarding the Ad E3 proteins
discussed above were derived from studies of cells in-
fected with replication-competent Ads that do or do not
express the E3 proteins. Those studies with Ad mutants
established that the E3 proteins are necessary for the
functions described, but they did not prove that they are
sufficient. In this communication, we describe the con-
struction and characterization of E1-minus replication-
defective Ad vectors that express all the E3 proteins,
express only RID plus E3-14.7K, express only RID, or
express only E3-14.7K. In these vectors, the natural E3
region is deleted, and the E3 proteins are synthesized
from an expression cassette, apparently by alternative
splicing, from the cytomegalovirus (CMV) immediate-
early promoter in the deleted E1 region. The E3 proteins
exert the expected functions.
RESULTS
The adenovirus vectors express RID and/or E3-14.7K
as expected
The vectors are shown schematically in Fig. 1. Exper-
iments were conducted to examine whether the E3 pro-
teins are synthesized by these vectors. A549 cells were
mock-infected or infected with 50 plaque forming units
(PFU) per cell of the vectors. Proteins were extracted at
1, 2, and 3 days postinfection (p.i.), and the RID, RID,
and E3-14.7K proteins were examined by immunoblot.
The E3 proteins were not obtained from mock-infected
cells (Fig. 2, lane m). RID was expressed as two bands
from the Ad/RID/14.7K vector (Fig. 2A, lanes a, e, i) and
from the Ad/RID vector (Fig. 2A, lanes c, g, k) at 1 through
3 days p.i. RID was seen at 2 and 3 days p.i. from Ad/E3
(Fig. 2A, lanes h and l). The two bands observed are
characteristic of RID extracted from cells infected with
Ad5, Ad2, or rec700 (an Ad5-Ad2-Ad5 recombinant)
(Tollefson et al., 1990b). With rec700, the upper band is
the entire 91 amino acid polypeptide including the initi-
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ator methionine, and the lower band is the polypeptide
with the N-terminal 22 amino acids cleaved away (Krajcsi
et al., 1992a). The upper and lower bands are joined by
a disulfide bond at amino acid 31 (Hoffman et al., 1992).
RID was not obtained from cells infected with Ad/14.7K
(Fig. 2A, lanes b, f, and j).
RID was expressed as multiple bands at 1, 2, and 3
days p.i. in cells infected with Ad/RID/14.7K, Ad/RID, or
Ad/E3 (Fig. 2B). In rec700-infected cells, RID is also
observed as multiple bands (Tollefson et al., 1990a).
These bands result because RID is both phosphory-
lated and O-glycosylated; the upper band corresponds to
molecules that are both phosphorylated and O-glycosy-
lated, and the lower bands are molecules with different
permutations of phosphorylation and glycosylation
(Krajcsi et al., 1992b,c; Krajcsi and Wold, 1992). RID was
not obtained from mock-infected cells (Fig. 2B, lane m) or
from cells infected with Ad/14.7K (Fig. 2B, lanes b, f,
and j).
E3-14.7K was expressed at 1, 2, and 3 days p.i. by
Ad/RID/14.7K (Fig. 2C, lanes a, e, and i), Ad/14.7K (Fig.
2C, lanes b, f, and j), or Ad/E3 (Fig. 2C, lanes d, h, and l).
One to four bands were observed. When analyzed by
specific immunoprecipitation of E3-14.7K from 35S-la-
beled cells, three bands are usually seen in cells in-
fected with rec700 or Ad2, and two bands are seen with
FIG. 1. Schematic of the expression cassettes for the E3 proteins expressed in the Ad vectors. In these vectors, the expression cassettes are
inserted into the deleted E1 region, and the natural E3 transcription unit is deleted. With all vectors, the CMV promoter drives transcription. The E3
transcription unit in all the vectors is derived from rec700, an Ad5-Ad2-Ad5 recombinant that contains the Ad5 EcoRI-A fragment [nucleotide (nt) 1 to
27,332 in the Ad5 genome], the Ad2 EcoRI-D fragment (nt 27,373 to 30,047 in the Ad2 genome), and the Ad5 EcoRI-B fragment (nt 30,050 to 35,935
in the Ad5 genome). The numbering of the E3 region of rec700 is described by Cladaras and Wold (1985), Cladaras et al. (1985), and Wold et al. (1986).
Nucleotide 1 is the major transcription initiation site, and it corresponds to nt 27,568 and 27,609 in the genomes of Ad5 and Ad2, respectively. Ad/E3
contains the E3 transcription unit of rec700 from nt 39 (in the E3 promoter) to nt 3521 (downstream of the E3B polyadenylation site). The dashed
carets indicate predicted alternative splicing for putative mRNAs a–h as has been shown for the E3 transcription unit in its natural position in the E3
region of the genome (Cladaras et al., 1985). For example, mRNA a is predicted to contain an exon from nt 1 to the 372 5-splice site and the 372
to 768 splice, and it would be polyadenylated at the E3A poly(A) site. mRNA a codes for the 6.7K and gp19K proteins. mRNA f should contain an exon
from 1 to 372, the 372 to 768 splice, an exon from 768 to 951, a splice from the 951 5-splice site to the 3 splice site at 2157, and then an exon from
2157 to the E3B poly(A) site. mRNA f codes for RID and RID. mRNA h, which codes for 14.7K, would be similar to mRNA f except the 3 splice is
at 2880 instead of 2157. Ad/RID/14.7K is predicted to contain a short exon downstream of the CMV promoter, a splice as indicated, another short exon
that is continuous with rec700 sequences from 912 to 1054 which in turn is continuous with 2121. The dashed lines indicate that sequences are
deleted. Splices occur from the 5 splice site at 951 to the 3 splice sites at 2157 (this mRNA encodes RID and RID) or at 2880 (this mRNA encodes
14.7K). With Ad/RID, only one mRNA is predicted that uses the 951 to 2157 splice and encodes RID and RID. With Ad/14.7K, only one mRNA is
predicted that uses the 951 to 2880 splice and encodes 14.7K.
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Ad5 (Tollefson and Wold, 1988; Gooding et al., 1988, 1990;
Horton et al., 1990; Ranheim et al., 1993). Two or three
bands of E3-14.7K have also been detected in immuno-
blots of mouse cells infected with rec700, in mouse cells
stably expressing E3-14.7K, and in cells of mice trans-
genic for E3-14.7K (Horton et al., 1991; Harrod et al., 1998;
Li et al., 1999). The explanation for these bands is un-
known. We conclude that our vectors synthesize the
RID, RID, and E3-14.7K proteins in forms that resem-
ble those seen with wild-type Ad-infected cells.
Indirect immunofluorescence studies were conducted
to investigate not only the expression of the RID and
E3-14.7K proteins from these Ad vectors, but also the
intracellular localization of the proteins. A549 cells were
infected at 50 PFU/cell of the vectors, then at 24 or 48 h
p.i., cells were fixed and immunostained for RID or
E3-14.7K. With Ad/RID/14.7K (Figs. 3A and 3B) and Ad/
RID (Figs. 3E and 3F), RID was observed in the plasma
membrane, intracellular membranes, and intracellular
vesicles. Localization of RID to the plasma and intra-
cellular membranes also occurs in cells infected with
rec700 (Stewart et al., 1995) as well as in COS cells
transiently transfected with plasmids that express RID
and RID (Tollefson et al., 1998). The presence of RID
on the plasma membrane implies that RID is expressed
as well, inasmuch as RID does not localize efficiently to
the plasma membrane in the absence of RID (Stewart
et al., 1995; Tollefson et al., 1998). The vesicular pattern
seen with Ad/RID/14.7K and Ad/RID is not usually ob-
served in cells infected by rec700 or Ad5, but it is seen
in transiently transfected COS cells (Tollefson et al.,
1998). Perhaps an Ad protein expressed by rec700 and
Ad5 but not by these Ad vectors or plasmid vectors
obscures or reduces the formation of these vesicles. In
any case, RID appears to be as functional when ex-
pressed from these vectors as it is when it is expressed
from wild-type Ad (Tollefson et al., 1998; Benedict et al.,
2001) (see below).
With Ad/RID/14.7K (Figs. 3C and 3D) and Ad/14.7K
(Figs. 3G and 3H), E3-14.7K was localized throughout the
cells, apparently including the nuclei but excluding the
nucleoli. The diffuse, somewhat lacy, staining pattern is
very similar to that seen for E3-14.7K in cells infected
with wild-type Ad (data not shown). The pattern is similar
FIG. 3. Immunofluorescence of RID and/or E3-14.7K expressed
from Ad vectors. A549 cells were infected with 20 PFU/cell of Ad/RID/
14.7K, Ad/RID, or Ad/14.7K, fixed at 24 or 48 h p.i. and then immuno-
stained for RID or E3-14.7K, as indicated.
FIG. 2. Ad/14.7K, Ad/RID, Ad/14.7K, and Ad/E3 express the expected
E3 proteins. Cells were infected with 50 PFU/cell of the indicated
vectors. At 1, 2, and 3 days p.i., proteins were extracted and analyzed
by immunoblot using antisera against RID (A), RID (B), or E3-14.7K
(C).
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to that reported by other workers in murine C3HA cells
constitutively expressing E3-14.7K, except that those au-
thors noted that the E3-14.7K staining was primarily cy-
toplasmic (Li et al., 1998).
We conclude that the Ad/RID/14.7K, Ad/RID, and Ad/
14.7K vectors express RID and/or 14.7K as expected, and
that the proteins are localized in the cell in a manner
similar to that seen with wild-type Ad (with the exception
of the RID vesicular pattern, as noted above).
RID is sufficient to clear Fas and EGFR from the cell
surface
We have shown previously that in cells infected with
wild-type Ad, Fas and EGFR are removed from the cell
surface (Carlin et al., 1989; Tollefson et al., 1991, 1998).
Using virus mutants that lack the entire E3 region or the
E3 genes individually, we showed that RID is required for
these receptors to be downregulated (Carlin et al., 1989;
Tollefson et al., 1991, 1998). Others have reported similar
results for Fas (Shisler et al., 1997; Elsing and Burgert,
1998). Here we have addressed whether RID expressed
from our E1-minus vectors is sufficient to clear these
receptors from the cell surface. Cells were mock-infected
or infected with rec700 (wild-type Ad) or the vectors. At
24 h p.i., Fas and EGFR were measured independently
on the cell surface by flow cytometry. Mock-infected cells
stained brightly for both receptors (Fig. 4). With rec700,
little or no staining for the receptors was observed,
indicating that the receptors had been cleared from
the cell surface (Fig. 4). With Ad/E3, Ad/RID/14.7K, and
Ad/RID, the vectors that synthesize RID, both Fas and
EGFR, were cleared to the same extent as with rec700. In
contrast, with the empty Ad/null vector (CMV promoter in
the E1 region but no E3 genes) or with Ad/14.7K, which
expresses the 14.7K protein but not RID, staining for both
receptors was as strong as with mock-infected cells (Fig.
4). These results, especially those with Ad/RID, indicate
that RID is sufficient to clear Fas and EGFR from the cell
surface.
RID is sufficient to internalize cell-surface EGFR and
Fas into putative endosomes and lysosomes
EGFR is well known to be internalized from the cell
surface into endosomes (Schlessinger, 2000). These en-
dosomes then transfer the EGFR cargo through the tu-
bulovesicular network to late endosomes which fuse
with lysosomes, resulting in degradation of EGFR. RID
has been shown to be necessary in the context of Ad
infection to force EGFR into endosomes (Carlin et al.,
1989; Tollefson et al., 1991). RID has a similar effect on
Fas (Tollefson et al., 1998).
We have addressed whether RID expressed from our
vectors is sufficient to force Fas and EGFR into vesicles.
Cells were mock-infected or infected with Ad/E3, Ad/RID/
14.7K, Ad/RID, or Ad/14.7K, and at 20–21 h p.i. the cells
were fixed and immunostained for Fas or EGFR. With
mock-infected cells, all cells had a cobblestone appear-
ance, indicating that Fas and EGFR were on the cell
surface (Fig. 5A). This was also true with cells infected by
Ad/14.7K, which does not express RID (Fig. 5D). EGFR
was much more abundant than Fas. With the three vec-
tors that express RID, namely Ad/E3, Ad/RID/14.7K, and
Ad/RID, Fas and EGFR were no longer on the cell surface
but rather were in numerous vesicles (Figs. 5B, 5C, and
5E). These vesicles are very likely endosomes and lyso-
somes because they appear identical to the vesicles
seen in wild-type Ad-infected cells (Carlin et al., 1989;
Tollefson et al., 1991, 1998).
RID is sufficient to inhibit apoptosis through the Fas
pathway
If the RID-expressing vectors cause Fas to be inter-
nalized from the cell surface into endosomes and lyso-
somes where Fas is degraded, then these vectors
should inhibit apoptosis mediated through the Fas path-
way. A549 cells were mock-infected or infected with
rec700 or the Ad vectors. At 25 h p.i., the cells were
treated with 20, 100, or 500 ng/ml of a monoclonal anti-
body to Fas that triggers Fas-induced apoptosis. Cyclo-
heximide (25 g/ml) was included to increase the sen-
FIG. 4. Vectors that express RID clear Fas and EGFR from the surface
of cells. HeLa cells were mock-infected or infected with 50 PFU/cell of
rec700 or 5–20 PFU/cell of the indicated viruses. At 24 h p.i., the
presence of Fas or EGFR on the cell surface was analyzed by flow
cytometry.
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sitivity of the cells to the Fas agonist antibody (Tollefson
et al., 1998). After 28 h of treatment, cell lysis was deter-
mined based on release of lactate dehydrogenase into
the culture medium (Tollefson et al., 1998). Strong lysis
was observed at all three antibody concentrations with
mock-infected cells and cells infected with Ad/14.7K (Fig.
6). However, little or no lysis was seen with rec700,
Ad/E3, Ad/RID/14.7K, or Ad/RID (Fig. 6). We conclude that
RID expressed from these E1-minus Ad vectors is suffi-
cient to inhibit Fas-induced apoptosis.
DISCUSSION
We have prepared three E1-minus replication-defec-
tive Ad vectors that express the E3 RID and E3-14.7K
proteins from expression cassettes inserted into the E1
region. As shown by immunoblotting and immunofluo-
rescence, the Ad/RID/14.7K vector synthesizes both RID
and E3-14.7K, Ad/RID synthesizes only RID, and Ad/14.7K
synthesizes only E3-14.7K. We have also constructed and
analyzed a similar vector named Ad/E3 that expresses
all E3 proteins (K. Toth et al., unpublished data). As
shown here for comparison, the Ad/E3 vector synthe-
sizes RID and E3-14.7K, although at somewhat lower
levels than the other vectors; this makes sense because
any given pre-mRNA synthesized by Ad/E3 can give rise
to mRNAs for the E3-12.5K, E3-6.7K, E3-gp19K proteins in
addition to RID, RID, and E3-14.7K (Fig. 1).
We have demonstrated that all the vectors that ex-
press RID display three of the functions previously attrib-
uted to RID using Ad E3 mutants. First, the vectors clear
Fas and EGFR from the cell surface, as indicated by flow
cytometry and immunofluorescence using antisera to
Fas or EGFR. Second, Fas and EGFR are internalized into
vesicles, presumably endosomes and lysosomes. Third,
FIG. 6. Vectors that express RID protect infected cells against apo-
ptosis induced by an anti-Fas agonist antibody. A549 cells were mock-
infected or infected with 75 PFU/cell of rec700 or 5–20 PFU/cell of the
vectors. At 25 h p.i., cells were treated with 20, 100, or 500 ng/ml of the
CH-11 agonist monoclonal antibody against Fas, plus 25 g/ml of
cycloheximide. After 28 h of treatment, cell lysis was determined based
on release of lactate dehydrogenase from cells into the culture me-
dium.
FIG. 5. Vectors that express RID force Fas and EGFR from the cell
surface into vesicles. A549 (EGFR) or HeLa (Fas) cells were mock-
infected or infected with 5–20 PFU/cell of Ad vectors. At 20–21 h p.i.,
cells were fixed and analyzed by indirect immunofluorescence for Fas
or EGFR.
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the RID-expressing vectors inhibit apoptosis through the
Fas pathway as judged by release of lactate dehydroge-
nase from cells. None of these functions was seen with
the Ad empty vector or with the Ad/14.7K vector which
expresses only E3-14.7K. These results indicate that RID
is not only necessary to clear Fas and EGFR from the cell
surface and protect against Fas-mediated apoptosis, RID
also is sufficient for these functions.
This conclusion is in accord with our earlier studies
showing that transient cotransfection of COS cells with
two plasmid vectors, one expressing only RID and the
other expressing only RID, caused Fas to be removed
from the cell surface into vesicles (Tollefson et al., 1998).
Further, when these plasmid vectors were transiently
cotransfected into MCF-7 cells, Fas-mediated apoptosis
was significantly inhibited (Tollefson et al., 1998). This
conclusion is also in accord with the study by Elsing and
Burgert (1998) showing that in 293 cells stably express-
ing RID and RID, cell-surface Fas levels are very low.
The caveat associated with this latter study is that the
stable cell lines may have developed unknown proper-
ties that obscure RID function. However, there are also
caveats associated with the conclusions derived from
the analysis of our vectors. First, E1-minus Ad vectors
have been reported to activate the RAS-ERK pathway
and to induce synthesis of interleukin 8 within minutes
following infection (Bruder and Kovesdi, 1997). This ob-
servation could leave open the possibility that RID must
function together with one or more cellular proteins that
are induced through these pathways via the interaction
of the virion with the cell. However, even if this is true, our
data indicate that RID is the only E3 protein that down-
regulates Fas and EGFR. The second caveat is that
E1A-minus Ads can, under circumstances of high multi-
plicity of infection and long periods (2 days) after in-
fection, express other Ad proteins in an E1A-independent
manner (Montell et al., 1984). Thus, we cannot formally
exclude the possible involvement of other Ad proteins
despite the fact that we have not observed other Ad
proteins to be synthesized under the conditions of our
experiments (data not shown).
Studies with Ad mutants in the mouse C3HA cell line
have indicated that E3-14.7K is required to inhibit TNF-
induced apoptosis (Gooding et al., 1988, 1990). E3-14.7K
is apparently sufficient to inhibit TNF-induced apoptosis,
inasmuch as E3-14.7K stably expressed in the mouse
C3HA and C127 cell lines render them resistant to TNF
(Horton et al., 1991; Krajcsi et al., 1996). TNF-induced
apoptosis was also inhibited by our Ad/14.7K vector (data
not shown).
There is a report that an Ad E1-minus vector or a
plasmid vector, each expressing E3-14.7K, inhibits apo-
ptosis though the Fas pathway in 293 and A549 cells
following infection or transient transfection, respectively
(Chen et al., 1998). E3-14.7K also blocked apoptosis
when it was cotransfected with plasmids expressing
FasL, FADD, or FLICE (caspase-8) (Chen et al., 1998). In
the same study, E3-14.7K and FLICE were shown to
interact in vitro using a co-immunoprecipitation assay. In
our work reported here, the Ad/14.7K vector did not
inhibit Fas-mediated apoptosis (Fig. 6), despite the fact
that this vector expresses E3-14.7K (Fig. 3). Further ex-
periments are required to explain these differences.
MATERIALS AND METHODS
Construction of the vectors
The SrfI-NdeI DNA fragment of pm734.1 (Tollefson et
al., 1996) corresponding to nucleotide 39 to 3521 of the
E3 rec700 transcription map (Cladaras et al., 1985; Wold
et al., 1986) was blunt-ended using the Klenow enzyme
and cloned into the SmaI site of pBSSK () (Invitrogen),
resulting in the plasmid designated p1721. The E3 region
containing the BamHI-SalI fragment of the plasmid was
subcloned into polylinker sites BamHI and XhoI of the
expression vector pcDNA3.1Zeo () (Invitrogen), thus
giving the pm734.1 E3 expression plasmid p181. The
plasmid was shown to express all known rec700 E3
proteins except ADP in transient transfection experi-
ments at levels comparable to wild-type virus infections
(K. Toth, unpublished data). The adp gene is mutated in
pm734.1 to eliminate expression of ADP. Presumably,
expression of multiple E3 genes in p181 occurs via al-
ternative splicing of transcripts, as is shown for E3 genes
in the natural viral background (Brady et al., 1992; Scaria
and Wold, 1994; Wold et al., 1995).
To obtain vectors for separate expression of E3 pro-
teins, further modifications were introduced to p181. The
SpeI-SmaI fragment of pCI (Promega) carrying the CMV
promoter and chimeric intron was used to replace the
SpeI-SunI B-fragment (the SunI site was blunted using
Klenow) in p181. A SunI site is located at nt 912 of the
rec700 E3 transcription unit; the substitution removes the
first intron (nt 372–768). The resulting plasmid p304 has
all E3 genes except 12.5K, which overlaps with the E3
first intron. The control plasmid without an intron did not
give detectable expression. The intron of pCI was suffi-
cient for expression of the remaining E3 genes. Plasmid
p304 was checked for expression in transient transfec-
tion experiments and shown to express all E3 proteins
except 12.5K and ADP (data not shown). Plasmid p304
has the 6.7K, gp19K, adp (mutated), RID, RID, and
14.7K genes. Plasmid p344 is a result of a PacI (1054
nt)-StuI (2121 nt) (PacI was T4 polymerase blunted) de-
letion in the E3 part of p304, removing the 6.7K, gp19K,
and adp genes and leaving the splicing signals and the
RID, RID, and 14.7K genes intact. Plasmid p431 is a
deletion of BglII (2900 nt)-BglII (3251 nt) in the E3 part of
p344, thus removing additionally the 14.7K gene and
leaving intact the RID and RID genes and the corre-
sponding splicing signals. Plasmid p358 is a PacI (1054
nt) (T4 polymerase blunted)-SspI (2604 nt) deletion in the
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E3 portion of p304, removing the 6.7K, gp19K, adp, RID,
and RID, genes, leaving intact the 14.7K gene and
splicing signals. Plasmids p344, p431, and p358 express
corresponding E3 genes as judged from results of tran-
sient transfection experiments (data not shown).
Plasmids pOD1, pOD2, and pOD3 are the result of
subcloning of MfeI-ClaI fragments with E3 gene expres-
sion cassettes from p344 (RID, 14.7K), p358 (14.7K only),
and p431 (RID only), correspondingly, into EcoRI and ClaI
sites of the pE1sp1A shuttle plasmid (Microbix, To-
ronto, Ontario). Plasmids pOD1, pOD2, and pOD3, unlike
parental plasmids, do not have any other poly(A) signals
except the E3B poly(A) signal. We have found the ade-
novirus E3B poly(A) signal to be stronger than the bovine
growth hormone or SV40 poly(A) signals (data not
shown).
Plasmids pOD1, pOD2, and pOD3 were cotransfected
along with pBHG10 (Microbix) into 293 cells. The result-
ing viruses were plaque-purified three times, expanded
in 293 suspension cultures, purified by CsCl gradient
centrifugation, and titered on 293 cells.
Immunoblots
A549 cells were infected with different viruses at mul-
tiplicities of 50 PFU/cell. The cells were harvested at
various times p.i. by scraping them off after three washes
with PBS. The protein concentration was determined by
the Bio-Rad DC Protein Assay Kit (Bio-Rad Laboratories,
Hercules, CA), and 10 g protein of each sample was
electrophoresed on a 15% SDS–polyacrylamide gel. The
proteins were electroblotted onto a Immobilon PVDF
membrane (Millipore, Bedford, MA) using a Bio-Rad
Trans-Blot SD Semi-Dry Electrophoretic Transfer Cell
(Bio-Rad Laboratories). The membranes were incubated
overnight at 4°C in TBST (50 mM Tris–HCl pH 7.6, 150
mM NaCl, 0.2% Tween20) containing 10% dry milk (Car-
nation) and then probed with rabbit polyclonal antibodies
raised against RID, RID, and 14.7K peptides, respec-
tively (Tollefson and Wold, 1988; Tollefson et al., 1990a,b).
The secondary antibody was goat anti-rabbit HRP and
(Cappel, Durham, NC). The bands were visualized via the
ECL protocol (Amersham Pharmacia, Arlington Heights,
IL).
Indirect immunofluorescence microscopy
A549 or HeLa cells were plated on glass coverslips.
Cells were mock-infected or infected at 50 PFU/cell with
wild-type rec700 virus or with 5–20 PFU/cell of the Ad
vectors. At 20–24 or 48 h p.i. (as indicated in the figure
legends), cells were fixed for immunostaining. For EGFR
and RID staining, cells were fixed in methanol (20°C)
for 10 min. For Fas and E3-14.7K staining, cells were fixed
in paraformaldehyde (3.7% in PBS) for 10 min and were
then permeabilized with methanol (20°C) for 6 min.
Cells were rehydrated with three PBS washes and
stained with primary antibodies diluted in PBS/1% BSA/
0.1% sodium azide. EGFR and Fas antibodies (Nos. 528
and C-20, respectively; Santa Cruz Biotechnology, Santa
Cruz, CA) were diluted to 1 g/ml. RID (Tollefson et al.,
1990a) and E3-14.7K (Tollefson and Wold, 1988) antisera
were diluted 1:250 and 1:300, respectively. Secondary
antibodies (Cappel/ICN) were diluted 1:50. Affinity-puri-
fied goat anti-rabbit immunoglobulin G (IgG)-fluorescein
isothiocyanate (FITC) conjugate was used for Fas, RID,
and E3-14.7K staining; affinity-purified goat anti-mouse
IgG-rhodamine isothiocyanate (RITC) conjugate was
used for EGFR staining. Mounting medium contained
p-phenylenediamine to prevent fading. Cells were pho-
tographed on Tmax 400 film on a Nikon Optiphot micro-
scope equipped with epifluorescence. Film was devel-
oped in Diafine developer and fixed in Kodak fixer.
Flow cytometry
HeLa cells were mock-infected or infected with 5–20
PFU/cell of the Ad vectors and staining began at approx-
imately 24 h p.i. Live cells were incubated on ice with
mouse monoclonal primary antibodies in fluorescence-
activated cell sorter buffer. The EGFR antibody (No. 528,
Santa Cruz) was diluted to 1 g/ml; the Fas antibody
(M38; ATCC) was used at a 1:4 dilution of culture super-
natant. The secondary antibody was affinity-purified goat
anti-mouse IgG-FITC conjugate (whole molecule; Cap-
pel/ICN). Cells were analyzed on a FACScaliber flow
cytometer using Cell Quest software. The figures are
three-dimensional overlays of the flow cytometry data.
Each curve was calculated from 10,000 gated events.
LDH assay
A549 cells were mock-infected, infected with 75 PFU/
cell of rec700, or were infected with 5–20 PFU/cell of the
Ad vectors. At 4.5 h p.i., cells were trypsinized and 2.8 
104 cells were plated per well in 96-well plates. At 25 h
p.i., CHX (25 g/ml final concentration) and Fas agonist
monoclonal antibody CH-11 (20–500 ng/ml final concen-
tration) were added to the 96-well plates. After 28 h of
treatment, supernatant samples were collected and as-
sayed for lactate dehydrogenase (LDH) activity using the
CytoTox96 assay (Promega, Madison, WI) (Tollefson et
al., 1996). Parallel wells treated with CHX only were used
for total lysis controls using lysis buffer included in the
kit. Percentage specific lysis was determined as follows:
percent specific lysis  (absorbance with treatment 
absorbance with CHX)/(maximum absorbance  absor-
bance with CHX)  100.
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